45 CFR § 180 compliance
F · 50
This hospital published little of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
●Discounted cash price
○Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
26,625
Insurances with rates
13
CPT / HCPCS codes
12,086
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| RX-137245 | NUSINERSEN (PF) 12 MG/5 ML INTRATHECAL SOLUTION | $796,184 | $318,473 | — | — | 0 |
| RX-137245 | NUSINERSEN (PF) 12 MG/5 ML INTRATHECAL SOLUTION | $796,184 | $318,473 | — | — | 0 |
| RX-202721 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $651,168 | $260,467 | — | — | 0 |
| RX-202721 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $651,168 | $260,467 | — | — | 0 |
| RX-104852 | SIPULEUCEL-T IN LACTATED RINGERS 50 MILLION CELL/250 ML IV SUSPENSION | $416,007 | $166,403 | — | — | 0 |
| RX-104852 | SIPULEUCEL-T IN LACTATED RINGERS 50 MILLION CELL/250 ML IV SUSPENSION | $416,007 | $166,403 | — | — | 0 |
| RX-194980 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION | $312,577 | $125,031 | — | — | 0 |
| RX-194980 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION | $312,577 | $125,031 | — | — | 0 |
| 2740000001 | Hb Sup Shell Rc 274 Without Hcpcs | $283,740 | $113,496 | — | — | 0 |
| RX-116024 | GLUCARPIDASE 1,000 UNIT INTRAVENOUS SOLUTION | $276,201 | $110,480 | — | — | 0 |
| RX-116024 | GLUCARPIDASE 1,000 UNIT INTRAVENOUS SOLUTION | $276,201 | $110,480 | — | — | 0 |
| RX-108956 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $239,239 | $95,696 | — | — | 0 |
| RX-108956 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $239,239 | $95,696 | — | — | 0 |
| 3610266T01 | Hb Im/Repl Cartd Sinus Baroreflx Activ Dev Tot Syst | $206,142 | $82,457 | — | — | 0 |
| 3610268T01 | Hb Im/Repl Cartd Sins Barreflx Act Dev Pls Gen Only | $206,142 | $82,457 | — | — | 0 |
| 3613324901 | Hb Aicd Insertion-1 Or 2 Leads | $206,142 | $82,457 | — | — | 0 |
| 3613326401 | Hb Aicd Gnr Remove&Rpl-Biv | $206,142 | $82,457 | — | — | 0 |
| 3613327001 | Hb Aicd Sq Insert Gnr-1 Lead | $206,142 | $82,457 | — | — | 0 |
| RX-40917 | SODIUM BENZOATE 10 %-SODIUM PHENYLACETATE 10 % INTRAVENOUS SOLUTION | $205,322 | $82,129 | — | — | 0 |
| RX-40917 | SODIUM BENZOATE 10 %-SODIUM PHENYLACETATE 10 % INTRAVENOUS SOLUTION | $205,322 | $82,129 | — | — | 0 |
| 3610238T01 | Hb Atherectomy W/S&I Ileac Artery Each Vessel | $201,808 | $80,723 | — | — | 0 |
| 8153820406 | Hb Nmdp Coordation Fee/Cell Collection | $197,548 | $79,019 | — | — | 0 |
| RX-151258 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION | $195,636 | $78,254 | — | — | 0 |
| RX-151258 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION | $195,636 | $78,254 | — | — | 0 |
| RX-41815 | KIT FOR YTTRIUM-90-IBRITUMOMAB 3.2 MG/2 ML INTRAVENOUS | $194,515 | $77,806 | — | — | 0 |
| RX-41815 | KIT FOR YTTRIUM-90-IBRITUMOMAB 3.2 MG/2 ML INTRAVENOUS | $194,515 | $77,806 | — | — | 0 |
| RX-194075 | LEUPROLIDE 45 MG (PEDIATRIC 6 MONTH) SUBCUTANEOUS SYRINGE | $186,616 | $74,647 | — | — | 0 |
| RX-194075 | LEUPROLIDE 45 MG (PEDIATRIC 6 MONTH) SUBCUTANEOUS SYRINGE | $186,616 | $74,647 | — | — | 0 |
| RX-117842 | PEGASPARGASE 750 UNIT/ML INJECTION SOLUTION | $182,520 | $73,008 | — | — | 0 |
| RX-117842 | PEGASPARGASE 750 UNIT/ML INJECTION SOLUTION | $182,520 | $73,008 | — | — | 0 |
| RX-216794 | PEGLOTICASE 8 MG/50 ML INTRAVENOUS SOLUTION | $179,967 | $71,987 | — | — | 0 |
| RX-216794 | PEGLOTICASE 8 MG/50 ML INTRAVENOUS SOLUTION | $179,967 | $71,987 | — | — | 0 |
| RX-206004 | LEUPROLIDE 45 MG (PEDIATRIC 6 MONTH) INTRAMUSCULAR SYRINGE KIT | $177,171 | $70,869 | — | — | 0 |
| RX-206004 | LEUPROLIDE 45 MG (PEDIATRIC 6 MONTH) INTRAMUSCULAR SYRINGE KIT | $177,171 | $70,869 | — | — | 0 |
| RX-107664 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $170,465 | $68,186 | — | — | 0 |
| RX-107664 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $170,465 | $68,186 | — | — | 0 |
| RX-201868 | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN 27 MCI/ML (1,000 MBQ/ML) IV SOLN | $159,311 | $63,724 | — | — | 0 |
| RX-201868 | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN 27 MCI/ML (1,000 MBQ/ML) IV SOLN | $159,311 | $63,724 | — | — | 0 |
| RX-146166 | INOTUZUMAB OZOGAMICIN 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) IV SOLN | $157,028 | $62,811 | — | — | 0 |
| RX-146166 | INOTUZUMAB OZOGAMICIN 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) IV SOLN | $157,028 | $62,811 | — | — | 0 |
| 278L867901 | Hb Sup Shell Rc 278 With L8679 Hcpcs | $151,328 | $60,531 | — | — | 0 |
| 3610408T01 | Hb Insj/Rplc Car Modulj Sys Pls Gen Transvns Eltrd | $148,269 | $59,308 | — | — | 0 |
| 3610409T01 | Hb Insj/Rplc Cardiac Modulj Sys Pls Generator Only | $148,269 | $59,308 | — | — | 0 |
| 3610414T01 | Hb Rmvl & Rpl Cardiac Modulj Sys Pls Generator Only | $148,269 | $59,308 | — | — | 0 |
| 3613323001 | Hb Aicd Insert Gnr-2 Exist Leads | $148,269 | $59,308 | — | — | 0 |
| 3613324001 | Hb Aicd Insert Gnr-1 Exist Lead | $148,269 | $59,308 | — | — | 0 |
| 3613326201 | Hb Aicd Gnr Remove & Repl-Sc | $148,269 | $59,308 | — | — | 0 |
| 3613326301 | Hb Aicd Gnr Remove & Repl-Dc | $148,269 | $59,308 | — | — | 0 |
| 274Q047901 | Hb Sup Shell Rc 274 With Q0479 Hcpcs | $139,179 | $55,672 | — | — | 0 |
| 4813328901 | Hb Cardiomems Impl Wrls P-Art Prs Snr L-T Hemodyn Mntr | $134,790 | $53,916 | — | — | 0 |
Showing top 50 of 26,625 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.